Grifols, S.A. (GRFS)

How it makes money

Grifols earns most of its money by selling plasma-derived medicines to hospitals, specialty pharmacies, home-care providers and distributors. In the United States it relies mainly on group purchasing organizations and distributors. Immunoglobulins alone made up about 54.3% of net revenue in 2025. The United States and Canada provided 56.5% of 2025 net revenue, the European Union 21.5% and the rest of the world 22.0%. Smaller revenue streams come from diagnostic reagents and instruments, biological materials for non-therapeutic use, and contract manufacturing.

Revenue by segment

Plasma medicines are hard to copy. A maker needs a large network of licensed collection centers, complex sterile factories and approvals from regulators, which take years and large sums to build. Grifols owns more than 400 centers and is one of only three global leaders. That scale is a real barrier for new entrants. The advantage is narrow rather than wide, for three reasons. Takeda, CSL and other competitors already sell similar 10% immunoglobulin products. New subcutaneous and non-plasma drugs, such as argenx's VYVGART, can take part of the market. The company also carries heavy debt.

Demand comes from patients with chronic conditions such as immune deficiencies, alpha-1 deficiency and bleeding disorders. They need treatment whatever the economy is doing. More diagnosis and more health spending in emerging markets support growth. The economy matters more for supply than for demand: plasma donations and their cost can change with economic conditions. Prices depend on public reimbursement policies.

Key risks

• Heavy debt — The company says its large debt could hurt its finances, limit how it reacts to change and make repayment harder. Debt covenants restrict how it runs the business. Part of the debt pays variable interest rates.
• Plasma supply — Plasma is the key raw material and comes from donors. The economy, pandemics, changes in immigration policy or trouble at collection centers could reduce supply. That would limit production and growth.
• Dependence on immunoglobulins — Immunoglobulins made up about 54.3% of 2025 net revenue. Any adverse event in that market, from competition or from new therapies, could seriously affect the company.
• Competition — Grifols faces rivals with greater financial resources, such as Takeda and CSL Behring. It also faces new subcutaneous and non-plasma-derived therapies.
• Manufacturing and safety — The production processes are complex and can be contaminated. Facilities must keep meeting good manufacturing rules. Product recalls, liability claims or new pathogens in the plasma supply could hurt the business.
• Pricing and reimbursement — US healthcare reform, government price controls in Europe and limits set by payers on reimbursement could reduce prices and margins.
• Currency, tariffs and China — A big change in the euro against the dollar, trade disputes and tariffs, and regulatory uncertainty in China could hurt results.
• Controlling family and short sellers — The Grifols family may have significant influence over the business. The company also says short sellers could push the share price down and lead to litigation.

In 2025 and 2024 no single customer accounted for more than 10% of the group's gross revenue. In 2023, one Biopharma customer accounted for about 10.37%. In the United States the company depends heavily on group purchasing organizations and distributors to sell its immunoglobulins.